New clinical information suggests that Novera Retatrutide, a dual-action therapy from Novo Nordisk, could provide a meaningful breakthrough in body management. Beyond many existing drugs, Retatrutide impacts both GLP-1 and the GIP hormone, potentially leading to enhanced reductions in body and be… Read More